AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Huang declares Israel Nvidia’s “second home” with record-breaking campus investment
2
Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal
3
Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation
4
Cyera raises $400 million at $9 billion valuation in Blackstone-led round
5
Zendesk acquires AI search startup Unleash for tens of millions
More news

Biopharma

6 stories about Biopharma
Rivki Stern Short Wave

Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund

16.08.22|CTech
The trial will study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa
ד"ר גילי הרט מנכ"לית ספלייסנס

SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF

13.05.21|Meir Orbach
The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research
רום לקריץ מושיק כהן קוטנר ו ניב בחנוף אומניקס מדיקל Omnix Medical

Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria

26.01.21|Meir Orbach
The novel agents developed by Omnix are designed as an alternative to classical antibiotics
נאסד"ק וול סטריט

Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering

09.04.19|CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland
נאסד"ק וול סטריט

Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq

24.07.18|Lilach Baumer
The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
default image

RedHill's Public Offering Spooks Investors, Sends Stock Down

09.11.17|Dror Reich
The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close